Antibody-based biological antiviral drugs for the prevention and treatment of acute respiratory viral infections in immunocompromised patients: focus on safety

The safety of drug therapy is of particular importance for immunocompromised patients. This aspect acquires high importance in the context of choosing tactics for the prevention and treatment of acute respiratory viral infections. The review presents data on the features of the antiviral immune response and common cold/influenza in patients with a burdened allergic history and a brief overview of the results of clinical studies on the effectiveness and safety of innovative biological antiviral drugs based on antibodies to biological targets – Ergoferon, Anaferon for children and Anaferon. The drugs have a targeted effect on the immune system in accordance with their pharmacological targets, have a significant evidence base, including a meta-analysis of clinical trials for each drug according to the indication "acute respiratory viral infections/influenza", as well as individual studies, including double-blind placebo-controlled randomized, with this pathology in immunocompromised patients. The article also includes the results of a generalized safety analysis of the use of the above drugs for the prevention and treatment of acute respiratory viral infections/influenza in patients with concomitant allergic and autoimmune pathology. The results of the conducted studies, meta-analyses and generalized statistical analysis of data on the use of the drugs Anaferon for children, Anaferon, Ergoferon for the prevention and treatment of acute respiratory viral infections/ influenza indicate proven efficacy and a favorable safety profile and allow us to recommend drugs for wide use with preventive and therapeutic purposes in accordance with indications, including patients with allergic and autoimmune pathology.